HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.6%

Neg 0% Neu 87.6% Pos 0%

HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $8 price target.